Chlamydia vaccine candidates and tools for chlamydial antigen discovery

2009 ◽  
Vol 8 (10) ◽  
pp. 1365-1377 ◽  
Author(s):  
Daniel D Rockey ◽  
Jie Wang ◽  
Lei Lei ◽  
Guangming Zhong
2007 ◽  
Vol 2007 ◽  
pp. 1-11 ◽  
Author(s):  
Eric Dumonteil

Over the past 15 years, DNA vaccines have gone from a scientific curiosity to one of the most dynamic research field and may offer new alternatives for the control of parasitic diseases such as leishmaniasis and Chagas disease. We review here some of the advances and challenges for the development of DNA vaccines against these diseases. Many studies have validated the concept of using DNA vaccines for both protection and therapy against these protozoan parasites in a variety of mouse models. The challenge now is to translate what has been achieved in these models into veterinary or human vaccines of comparable efficacy. Also, genome-mining and new antigen discovery strategies may provide new tools for a more rational search of novel vaccine candidates.


Vaccine ◽  
2016 ◽  
Vol 34 (38) ◽  
pp. 4602-4609 ◽  
Author(s):  
Karina Juhl Rasmussen ◽  
Andreas Holm Mattsson ◽  
Katrine Pilely ◽  
Cecilie Antoinette Asferg ◽  
Oana Ciofu ◽  
...  

2015 ◽  
Vol 9 ◽  
pp. 91-95 ◽  
Author(s):  
Valeria A. Judkowski ◽  
Radleigh G. Santos ◽  
Gonzalo Acevedo ◽  
Marc A. Giulianotti ◽  
Jon R. Appel ◽  
...  

2017 ◽  
Vol 24 (8) ◽  
Author(s):  
Arti Sharma ◽  
Sarita Rani ◽  
Syed Imteyaz Alam ◽  
Sarkaraisamy Ponmariappan
Keyword(s):  

2015 ◽  
Vol 13 (6) ◽  
pp. 462-478 ◽  
Author(s):  
Thorsten Demberg ◽  
Marjorie Robert-Guroff

2020 ◽  
Vol 17 ◽  
Author(s):  
Mehreen Ismail ◽  
Zureesha Sajid ◽  
Amjad Ali ◽  
Xiaogang Wu ◽  
Syed Aun Muhammad ◽  
...  

Background: Human Papillomavirus (HPV) is responsible for substantial morbidity and mortality worldwide. We predicted immunogenic promiscuous monovalent and polyvalent T-cell epitopes from the polyprotein of the Human Papillomavirus (HPV) using a range of bioinformatics tools and servers. Methods: We used immunoinformatics and reverse vaccinology-based approaches to design prophylactic peptides by antigenicity analysis, Tcell epitopes prediction, proteasomal and conservancy evaluation, host-pathogen protein interactions, and in silico binding affinity analysis. Results: We found two early proteins (E2 and E6) and two late proteins (L1 and L2) of HPV as potential vaccine candidates. Of these proteins (E2, E6, L1 & L2), 2-epitopes of each candidate protein for multiple alleles of MHC class I and II bearing significant binding affinity (>-6.0 kcal/mole). These potential epitopes for CD4+ and CD8+ T-cells were also linked to design polyvalent construct using GPGPG linkers. Cholera toxin B and mycobacterial heparin-binding hemagglutinin adjuvant with a molecular weight of 12.5 and 18.5 kDa were used for epitopes of CD4+ and CD8+ T-cells respectively. The molecular docking indicated the optimum binding affinity of HPV peptides with MHC molecules. This interaction showed that our predicted vaccine candidates are suitable to trigger the host immune system to prevent HPV infections. Conclusion: The predicted conserved T-cell epitopes would contribute to the imminent design of HPV vaccine candidates, which will be able to induce a broad range of immune-responses in a heterogeneous HLA population.


Sign in / Sign up

Export Citation Format

Share Document